339 related articles for article (PubMed ID: 34025072)
1. Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study.
Janczewska E; Kołek MF; Lorenc B; Klapaczyński J; Tudrujek-Zdunek M; Sitko M; Mazur W; Zarębska-Michaluk D; Buczyńska I; Dybowska D; Czauż-Andrzejuk A; Berak H; Krygier R; Jaroszewicz J; Citko J; Piekarska A; Dobracka B; Socha Ł; Deroń Z; Laurans Ł; Białkowska-Warzecha J; Tronina O; Adamek B; Tomasiewicz K; Simon K; Pawłowska M; Halota W; Flisiak R
World J Gastroenterol; 2021 May; 27(18):2177-2192. PubMed ID: 34025072
[TBL] [Abstract][Full Text] [Related]
2. Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection.
El-Sherif O; Jiang ZG; Tapper EB; Huang KC; Zhong A; Osinusi A; Charlton M; Manns M; Afdhal NH; Mukamal K; McHutchison J; Brainard DM; Terrault N; Curry MP
Gastroenterology; 2018 Jun; 154(8):2111-2121.e8. PubMed ID: 29535028
[TBL] [Abstract][Full Text] [Related]
3. Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era.
Brzdęk M; Zarębska-Michaluk D; Rzymski P; Lorenc B; Kazek A; Tudrujek-Zdunek M; Janocha-Litwin J; Mazur W; Dybowska D; Berak H; Parfieniuk-Kowerda A; Klapaczyński J; Sitko M; Sobala-Szczygieł B; Piekarska A; Flisiak R
World J Gastroenterol; 2023 Apr; 29(13):2015-2033. PubMed ID: 37155527
[TBL] [Abstract][Full Text] [Related]
4. Predictors of functional benefit of hepatitis C therapy in a 'real-life' cohort.
Steinebrunner N; Stein K; Sandig C; Bruckner T; Stremmel W; Pathil A
World J Gastroenterol; 2018 Feb; 24(7):852-861. PubMed ID: 29467555
[TBL] [Abstract][Full Text] [Related]
5. Treatment of HCV infection in Poland at the beginning of the interferon-free era-the EpiTer-2 study.
Flisiak R; Zarębska-Michaluk D; Janczewska E; Staniaszek A; Gietka A; Mazur W; Tudrujek M; Tomasiewicz K; Belica-Wdowik T; Baka-Ćwierz B; Dybowska D; Halota W; Lorenc B; Sitko M; Garlicki A; Berak H; Horban A; Orłowska I; Simon K; Socha Ł; Wawrzynowicz-Syczewska M; Jaroszewicz J; Deroń Z; Czauż-Andrzejuk A; Citko J; Krygier R; Piekarska A; Laurans Ł; Dobracki W; Białkowska J; Tronina O; Pawłowska M
J Viral Hepat; 2018 Jun; 25(6):661-669. PubMed ID: 29316039
[TBL] [Abstract][Full Text] [Related]
6. Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China.
Yang Y; Wu FP; Wang WJ; Shi JJ; Li YP; Zhang X; Dang SS
World J Gastroenterol; 2019 Nov; 25(44):6551-6560. PubMed ID: 31802834
[TBL] [Abstract][Full Text] [Related]
7. Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients.
Zarębska-Michaluk D; Brzdęk M; Jaroszewicz J; Tudrujek-Zdunek M; Lorenc B; Klapaczyński J; Mazur W; Kazek A; Sitko M; Berak H; Janocha-Litwin J; Dybowska D; Supronowicz Ł; Krygier R; Citko J; Piekarska A; Flisiak R
World J Gastroenterol; 2022 Dec; 28(45):6380-6396. PubMed ID: 36533109
[TBL] [Abstract][Full Text] [Related]
8. Direct-acting antiviral therapy for hepatitis C: The initial experience of the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa.
Sonderup MW; Gogela N; Nordien R; Smuts H; Korsman S; Hardie D; Spearman CW
S Afr Med J; 2020 Jan; 110(2):112-117. PubMed ID: 32657680
[TBL] [Abstract][Full Text] [Related]
9. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
[TBL] [Abstract][Full Text] [Related]
10. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.
Verna EC; Morelli G; Terrault NA; Lok AS; Lim JK; Di Bisceglie AM; Zeuzem S; Landis CS; Kwo P; Hassan M; Manns MP; Vainorius M; Akushevich L; Nelson DR; Fried MW; Reddy KR
J Hepatol; 2020 Sep; 73(3):540-548. PubMed ID: 32243960
[TBL] [Abstract][Full Text] [Related]
11. Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders.
Dybowska D; Zarębska-Michaluk D; Rzymski P; Berak H; Lorenc B; Sitko M; Dybowski M; Mazur W; Tudrujek-Zdunek M; Janocha-Litwin J; Janczewska E; Klapaczyński J; Parfieniuk-Kowerda A; Piekarska A; Sobala-Szczygieł B; Dobrowolska K; Pawłowska M; Flisiak R
World J Gastroenterol; 2023 Jul; 29(25):4085-4098. PubMed ID: 37476581
[TBL] [Abstract][Full Text] [Related]
12. Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals.
Corma-Gómez A; Macías J; Téllez F; Freyre-Carrillo C; Morano L; Rivero-Juárez A; Ríos MJ; Alados JC; Vera-Méndez FJ; Merchante N; Palacios R; Granados R; Merino D; De Los Santos I; Pineda JA
Clin Infect Dis; 2020 Dec; 71(9):2354-2362. PubMed ID: 31754695
[TBL] [Abstract][Full Text] [Related]
13. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.
Maan R; van Tilborg M; Deterding K; Ramji A; van der Meer AJ; Wong F; Fung S; Sherman M; Manns MP; Cornberg M; Hansen BE; Wedemeyer H; Janssen HL; de Knegt RJ; Feld JJ
Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1821-1830.e6. PubMed ID: 27404965
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older.
Conti F; Brillanti S; Buonfiglioli F; Vukotic R; Morelli MC; Lalanne C; Massari M; Foschi FG; Bernabucci V; Serio I; Prati GM; Negri E; Badia L; Caraceni P; Muratori P; Vitale G; Porro A; Morotti M; Mazzella G; Andreone P
J Viral Hepat; 2017 Jun; 24(6):454-463. PubMed ID: 27976461
[TBL] [Abstract][Full Text] [Related]
15. Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection.
Weiler N; Zeuzem S; Welker MW
World J Gastroenterol; 2016 Nov; 22(41):9044-9056. PubMed ID: 27895394
[TBL] [Abstract][Full Text] [Related]
16. Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy.
Zarębska-Michaluk D; Buczyńska I; Simon K; Tudrujek-Zdunek M; Janczewska E; Dybowska D; Sitko M; Dobracka B; Jaroszewicz J; Pabjan P; Klapaczyński J; Laurans Ł; Mazur W; Socha Ł; Tronina O; Parczewski M; Flisiak R
Can J Gastroenterol Hepatol; 2019; 2019():4029541. PubMed ID: 30941326
[TBL] [Abstract][Full Text] [Related]
17. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure.
Degasperi E; Spinetti A; Lombardi A; Landonio S; Rossi MC; Pasulo L; Pozzoni P; Giorgini A; Fabris P; Romano A; Lomonaco L; Puoti M; Vinci M; Gatti F; Carolo G; Zoncada A; Bonfanti P; Russo FP; Aghemo A; Soria A; Centenaro R; Maggiolo F; Rovere P; Pasin F; Paon V; Faggiano G; Vario A; Grossi G; Soffredini R; Carriero C; Paolucci S; Noventa F; Alberti A; Lampertico P; Fagiuoli S;
J Hepatol; 2019 Dec; 71(6):1106-1115. PubMed ID: 31433303
[TBL] [Abstract][Full Text] [Related]
18. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study.
Romano A; Angeli P; Piovesan S; Noventa F; Anastassopoulos G; Chemello L; Cavalletto L; Gambato M; Russo FP; Burra P; Vincenzi V; Scotton PG; Panese S; Tempesta D; Bertin T; Carrara M; Carlotto A; Capra F; Carolo G; Scroccaro G; Alberti A
J Hepatol; 2018 Aug; 69(2):345-352. PubMed ID: 29551707
[TBL] [Abstract][Full Text] [Related]
19. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry.
Fernández Carrillo C; Lens S; Llop E; Pascasio JM; Crespo J; Arenas J; Fernández I; Baliellas C; Carrión JA; de la Mata M; Buti M; Castells L; Albillos A; Romero M; Turnes J; Pons C; Moreno-Planas JM; Moreno-Palomares JJ; Fernández-Rodriguez C; García-Samaniego J; Prieto M; Fernández Bermejo M; Salmerón J; Badia E; Salcedo M; Herrero JI; Granados R; Blé M; Mariño Z; Calleja JL
Hepatology; 2017 Jun; 65(6):1810-1822. PubMed ID: 28170112
[TBL] [Abstract][Full Text] [Related]
20. Experience of a Portuguese Center: Effectiveness of Direct-Acting Antiviral Therapy for Hepatitis C.
Falcão F; Lopes C; Viegas E; Perez R; Aldir I; Farinha H; Carvalho A; Mirco A; Marques S; Bana E Costa T; Miranda AC; Lebre L; Peixe P; Chagas C; Mansinho K; Correia JM
Acta Med Port; 2019 Mar; 32(3):189-194. PubMed ID: 30946789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
